These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37614155)

  • 21. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
    Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
    J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Racial inequity in medication treatment for opioid use disorder: Exploring potential facilitators and barriers to use.
    Hollander MAG; Chang CH; Douaihy AB; Hulsey E; Donohue JM
    Drug Alcohol Depend; 2021 Oct; 227():108927. PubMed ID: 34358766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. All-payer value-based contracting in organizations with Medicare ACOs.
    Mechanic RE
    Am J Manag Care; 2023 Nov; 29(11):601-604. PubMed ID: 37948647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. College students' perceived knowledge of and perceived helpfulness of treatments for opioid use disorder at two American universities.
    Andraka-Christou B; Nguyen T; Harris S; Madeira J; Totaram R; Randall-Kosich O; Atkins D; Ford J
    Am J Drug Alcohol Abuse; 2020 Sep; 46(5):589-603. PubMed ID: 32543922
    [No Abstract]   [Full Text] [Related]  

  • 26. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
    Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
    J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics of Rural Accountable Care Organizations (ACOs) – A Survey of Medicare ACOs with Rural Presence.
    Salako A; Zhu X; MacKinney AC; Ullrich F; Mueller K; ;
    Rural Policy Brief; 2015 May; (2015 8):1-4. PubMed ID: 26793816
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimization of Medication Use at Accountable Care Organizations.
    Wilks C; Krisle E; Westrich K; Lunner K; Muhlestein D; Dubois R
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1054-1064. PubMed ID: 28944730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of Rates of Overdose and Hospitalization After Initiation of Medication for Opioid Use Disorder in the Inpatient vs Outpatient Setting.
    Morgan JR; Barocas JA; Murphy SM; Epstein RL; Stein MD; Schackman BR; Walley AY; Linas BP
    JAMA Netw Open; 2020 Dec; 3(12):e2029676. PubMed ID: 33320266
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dental care utilization in Massachusetts before and after initiation of medication for opioid use disorder: A cross-sectional study of a state all-payer claims database.
    Simon L; Choudhary A; Ticku S; Barrow J; Tobey M
    J Public Health Dent; 2022 Sep; 82(4):461-467. PubMed ID: 34816438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimating the impact on initiating medications for opioid use disorder of state policies expanding Medicaid and prohibiting substance use during pregnancy.
    Choi S; Stein MD; Raifman J; Rosenbloom D; Clark JA
    Drug Alcohol Depend; 2021 Dec; 229(Pt A):109162. PubMed ID: 34768053
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug court utilization of medications for opioid use disorder in high opioid mortality communities.
    Marlowe DB; Theiss DS; Ostlie EM; Carnevale J
    J Subst Abuse Treat; 2022 Oct; 141():108850. PubMed ID: 35931014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patterns of clinic switching and continuity of medication for opioid use disorder in a Medicaid-enrolled population.
    Cole ES; Drake C; DiDomenico E; Sharbaugh M; Kim JY; Nagy D; Cochran G; Gordon AJ; Gellad WF; Pringle J; Warwick J; Chang CH; Kmiec J; Kelley D; Donohue JM
    Drug Alcohol Depend; 2021 Apr; 221():108633. PubMed ID: 33631544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are ACOs ready to be accountable for medication use?
    Dubois RW; Feldman M; Lustig A; Kotzbauer G; Penso J; Pope SD; Westrich KD
    J Manag Care Pharm; 2014 Jan; 20(1):17-21. PubMed ID: 24372456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of pharmacy services in accountable care organizations.
    Colla CH; Lewis VA; Beaulieu-Jones BR; Morden NE
    J Manag Care Spec Pharm; 2015 Apr; 21(4):338-44. PubMed ID: 25803767
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities.
    Mojtabai R; Mauro C; Wall MM; Barry CL; Olfson M
    Health Aff (Millwood); 2019 Jan; 38(1):14-23. PubMed ID: 30615514
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical leaders and providers' perspectives on delivering medications for the treatment of opioid use disorder in Veteran Affairs' facilities.
    Hawkins EJ; Danner AN; Malte CA; Blanchard BE; Williams EC; Hagedorn HJ; Gordon AJ; Drexler K; Burden JL; Knoeppel J; Lott A; Sayre GG; Midboe AM; Saxon AJ
    Addict Sci Clin Pract; 2021 Sep; 16(1):55. PubMed ID: 34488892
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Criminal problem-solving and civil dependency court policies regarding medications for opioid use disorder.
    Andraka-Christou B; Clark MH; Atkins DN; Del Pozo B
    Subst Abus; 2022; 43(1):425-432. PubMed ID: 34236297
    [No Abstract]   [Full Text] [Related]  

  • 39. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
    Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
    J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Total cost of care associated with opioid use disorder treatment.
    Toseef MU; Durfee J; Podewils LJ; Blum J; McEwen D; Hanratty R; Everhart R
    Prev Med; 2023 Jan; 166():107345. PubMed ID: 36370891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.